| Literature DB >> 28628672 |
Marie Verbanck1, Mickaël Canouil1, Audrey Leloire1, Véronique Dhennin1, Xavier Coumoul2, Loïc Yengo1, Philippe Froguel1,3, Odile Poulain-Godefroy1.
Abstract
Bisphenol A (BPA) exposure has been suspected to be associated with deleterious effects on health including obesity and metabolically-linked diseases. Although bisphenols F (BPF) and S (BPS) are BPA structural analogs commonly used in many marketed products as a replacement for BPA, only sparse toxicological data are available yet. Our objective was to comprehensively characterize bisphenols gene targets in a human primary adipocyte model, in order to determine whether they may induce cellular dysfunction, using chronic exposure at two concentrations: a "low-dose" similar to the dose usually encountered in human biological fluids and a higher dose. Therefore, BPA, BPF and BPS have been added at 10 nM or 10 μM during the differentiation of human primary adipocytes from subcutaneous fat of three non-diabetic Caucasian female patients. Gene expression (mRNA/lncRNA) arrays and microRNA arrays, have been used to assess coding and non-coding RNA changes. We detected significantly deregulated mRNA/lncRNA and miRNA at low and high doses. Enrichment in "cancer" and "organismal injury and abnormalities" related pathways was found in response to the three products. Some long intergenic non-coding RNAs and small nucleolar RNAs were differentially expressed suggesting that bisphenols may also activate multiple cellular processes and epigenetic modifications. The analysis of upstream regulators of deregulated genes highlighted hormones or hormone-like chemicals suggesting that BPS and BPF can be suspected to interfere, just like BPA, with hormonal regulation and have to be considered as endocrine disruptors. All these results suggest that as BPA, its substitutes BPS and BPF should be used with the same restrictions.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28628672 PMCID: PMC5476258 DOI: 10.1371/journal.pone.0179583
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Experimental design and analysis workflow.
BPA, BPS, BPF and DMSO: respectively Bisphenol A, S and F and dimethyl sulfoxide.
Numbers of differentially down and up-regulated (mRNA/lncRNA) probes amongst the 22,935 probes after the exposition of the pre-adipocytes to 10 nM or 10 μM of bisphenol shared between the concentrations for each bisphenol.
| 10 nM | shared | 10 μM | ||
|---|---|---|---|---|
| 846 | 211 | 774 | ||
| 417 | 126 | 1,106 | ||
| 1,173 | 387 | 748 | ||
| 367 | 60 | 323 | ||
| 216 | 46 | 1,228 | ||
| 621 | 133 | 989 |
Number of differentially down and up-regulated (mRNA/lncRNA) probes amongst the 22,935 probes after the exposition of the pre-adipocytes to 10 nM or 10 μM of bisphenol (A, F and S) during differentiation shared between BPA and BPS or BPF.
| 1,173 down | 367 up | 216 down | 621 up | ||
| 846 down | 524 | 0 | 43 | 4 | |
| 417 up | 0 | 65 | 0 | 77 | |
| 748 down | 323 up | 1,228 down | 989 up | ||
| 774 down | 260 | 2 | 226 | 1 | |
| 1,106 up | 3 | 110 | 8 | 223 | |
Fig 2Heatmap representation of significantly differentially expressed genes in the three bisphenols at 10 nM and 10 μM.
The represented values are log2 fold changes of the ratio of the expression in a given bisphenol and concentration over the control condition which is differentiated without any bisphenol. Genes (probes) highlighted in pink are significant for all concentrations of all bisphenols.
Numbers of differentially down and up-regulated miRNA probes amongst the 483 probes after the exposition of the pre-adipocytes to 10 nM or 10 μM of bisphenol shared between the concentrations for each bisphenol.
| 10 nM | shared | 10 μM | ||
|---|---|---|---|---|
| 39 | 2 | 18 | ||
| 33 | 0 | 13 | ||
| 61 | 3 | 11 | ||
| 40 | 3 | 8 | ||
| 0 | 0 | 50 | ||
| 12 | 4 | 48 |
Number of differentially down and up-regulated miRNA probes amongst the 483 probes after the exposition of the pre-adipocytes to 10 nM or 10 μM of bisphenol (A, F and S) during differentiation shared between BPA and BPS or BPF.
| 61 down | 40 up | 0 down | 12 up | ||
| 39 down | 32 | 0 | 0 | 0 | |
| 33 up | 0 | 26 | 0 | 0 | |
| 11 down | 8 up | 50 down | 48 up | ||
| 18 down | 7 | 0 | 3 | 0 | |
| 13 up | 0 | 5 | 0 | 2 | |
Fig 3Heatmap representation of significantly differentially miRNA in the three bisphenols at 10 nM and 10 μM.
The represented values are log2 fold changes of the ratio of the expression in a given bisphenol and concentration over the control condition which is differentiated without any bisphenol.
Enrichment analysis using Ingenuity Pathway Analysis on the lists of mRNA probes differentially expressed after exposition to the three bisphenols A, F and S at 10 nM and 10 μM.
| Name | p-value | Name | p-value | Name | p-value | ||
| Top canonical pathway | EIF2 Signaling | 1.40E-03 | Mouse Embryonic Stem Cell Pluripotency | 8.50E-05 | EIF2 Signaling | 1.05E-03 | |
| NAD Biosynthesis III | 1.54E-02 | Leptin Signaling in Obesity | 1.05E-04 | Acute Phase Response Signaling | 1.31E-03 | ||
| Aspartate Degradation II | 2.11E-02 | Role of NFAT in Cardiac Hypertrophy | 1.65E-04 | Inhibition of Matrix Metalloproteases | 1.53E-03 | ||
| Sorbitol Degradation I | 3.35E-02 | Human Embryonic Stem Cell Pluripotency | 3.42E-04 | Interferon Signaling | 5.91E-03 | ||
| Netrin Signaling | 4.08E-02 | PPAR/RXR Activation | 1.05E-03 | Heme Degradation | 6.09E-03 | ||
| Top Upstream Regulators | MYCN | 1.19E-04 | HNF4A | 2.76E-06 | TP53 | 1.14E-07 | |
| miR-124-3p (and miRNAs w/seed AAGGCAC) | 9.46E-04 | ESR1 | 1.86E-05 | MYC | 1.31E-06 | ||
| FAAH | 1.71E-03 | OSM | 3.21E-05 | HRAS | 2.04E-06 | ||
| TP53 | 1.93E-03 | P4HB | 7.74E-05 | TGFB1 | 3.63E-06 | ||
| phosphate | 2.42E-03 | MYCN | 1.40E-04 | ESR1 | 4.69E-06 | ||
| Diseases and Disorders | Cancer | 3.35E-02–3.56E-12 | Cancer | 1.14E-02–7.03E-14 | Cancer | 5.75E-03–4.62E-09 | |
| Organismal Injury and Abnormalities | 3.35E-02–3.56E-12 | Gastrointestinal Disease | 1.14E-02–7.03E-14 | Organismal Injury and Abnormalities | 6.08E-03–4.62E-09 | ||
| Gastrointestinal Disease | 3.35E-02–8.11E-09 | Hepatic System Disease | 1.10E-02–7.03E-14 | Infectious Diseases | 6.04E-03–1.56E-08 | ||
| Hepatic System Disease | 1.80E-02–8.11E-09 | Organismal Injury and Abnormalities | 1.14E-02–7.03E-14 | Gastrointestinal Disease | 6.06E-03–4.27E-08 | ||
| Reproductive System Disease | 3.35E-02–1.41E-07 | Renal and Urological Disease | 1.04E-03–3.70E-09 | Reproductive System Disease | 4.51E-03–1.09E-05 | ||
| Name | p-value | Name | p-value | Name | p-value | ||
| Top canonical pathway | Axonal Guidance Signaling | 8.60E-06 | Molecular Mechanisms of Cancer | 1.09E-03 | Death Receptor Signaling | 3.16E-04 | |
| Remodeling of Epithelial Adherens Junctions | 1.07E-04 | Aryl Hydrocarbon Receptor Signaling | 3.66E-03 | phagosome maturation | 1.08E-03 | ||
| Molecular Mechanisms of Cancer | 2.66E-04 | Glucocorticoid Receptor Signaling | 3.72E-03 | Mitochondrial Dysfunction | 1.49E-03 | ||
| Sertoli Cell-Sertoli Cell Junction Signaling | 5.92E-04 | Hepatic Fibrosis / Hepatic Stellate Cell Activation | 4.97E-03 | tRNA Charging | 1.63E-03 | ||
| Acute Phase Response Signaling | 6.69E-04 | Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 6.85E-03 | Oxidative Phosphorylation | 2.27E-03 | ||
| Top Upstream Regulators | beta-estradiol | 6.69E-13 | ESR1 | 1.14E-10 | TP53 | 2.10E-09 | |
| Vegf | 8.05E-13 | PDGF BB | 3.41E-10 | IND S1 | 5.50E-08 | ||
| TGFB1 | 9.82E-13 | TP53 | 7.02E-10 | IND S7 | 1.17E-07 | ||
| dexamethasone | 1.14E-11 | tretinoin | 1.47E-09 | CD 437 | 1.61E-07 | ||
| TNF | 1.38E-11 | dexamethasone | 3.13E-09 | MEL S3 | 1.86E-07 | ||
| Diseases and Disorders | Cancer | 8.16E-04–8.06E-22 | Cancer | 1.01E-03–7.01E-19 | Cancer | 6.27E-03–1.40E-15 | |
| Organismal Injury and Abnormalities | 8.16E-04–8.06E-22 | Organismal Injury and Abnormalities | 1.01E-03–7.01E-19 | Organismal Injury and Abnormalities | 6.27E-03–1.40E-15 | ||
| Gastrointestinal Disease | 7.98E-04–1.15E-16 | Gastrointestinal Disease | 9.91E-04–9.85E-17 | Gastrointestinal Disease | 6.27E-03–5.35E-13 | ||
| Reproductive System Disease | 7.25E-04–2.29E-16 | Reproductive System Disease | 7.69E-04–9.39E-15 | Reproductive System Disease | 6.00E-03–7.57E-12 | ||
| Endocrine System Disorders | 6.47E-04–1.67E-10 | Hepatic System Disease | 2.97E-04–2.42E-14 | Infectious Diseases | 5.45E-03–5.58E-09 | ||
For each bisphenol, the five most significantly enriched canonical pathways, top upstream regulators as well as diseases and disorders are displayed with the corresponding p-values. The enrichment is based on the comparison between the number of dysregulated gene involved in a given function in the dataset compared to the number expected by chance. The displayed range of p-values corresponds to the range of p-values encountered for the different annotations in this category.
List of differentially expressed probes deregulated for the three bisphenols A, F and S at 10 nM.
| BPA | BPS | BPF | ||||||
|---|---|---|---|---|---|---|---|---|
| ProbeName | GeneName | Entrez Gene Name | log2FC | P-value | log2FC | P-value | log2FC | P-value |
| A_23_P44139 | PRIM2 | primase (DNA) subunit 2 | 4.81E-05 | 3.78E-04 | 8.26E-03 | |||
| A_33_P3280044 | ANKRD11 | ankyrin repeat domain 11 | -0.227 | 7.52E-05 | -0.326 | 5.10E-07 | -0.264 | 7.51E-04 |
| A_19_P00315601 | XLOC_014512 | -0.687 | 8.34E-05 | -0.292 | 6.91E-04 | 0.224 | 1.39E-02 | |
| A_24_P232790 | CCDC177 | coiled-coil domain containing 177 | 2.81E-04 | 3.16E-04 | 1.33E-03 | |||
| A_23_P307310 | ACAN | aggrecan | -0.488 | 3.01E-04 | -0.4 | 6.10E-04 | -0.508 | 7.26E-04 |
| A_33_P3321657 | HSPG2 | heparan sulfate proteoglycan 2 | -0.367 | 4.39E-04 | -0.441 | 3.23E-08 | -0.293 | 7.05E-05 |
| A_23_P90143 | RPL13A | ribosomal protein L13a | -0.165 | 4.52E-04 | -0.156 | 9.83E-04 | -0.133 | 5.30E-03 |
| A_33_P3278407 | AFDN | afadin, adherens junction formation factor | -0.189 | 5.40E-04 | -0.249 | 3.09E-05 | -0.196 | 1.40E-03 |
| A_21_P0014132 | THC2690033 | -0.177 | 5.68E-04 | -0.241 | 1.60E-05 | -0.171 | 5.33E-04 | |
| A_24_P148235 | RPS27 | ribosomal protein S27 | -0.134 | 7.61E-04 | -0.115 | 4.68E-03 | -0.137 | 4.14E-03 |
| A_21_P0013977 | PCID2 | PCI domain containing 2 | -0.395 | 8.31E-04 | -0.429 | 1.07E-03 | -0.273 | 9.76E-03 |
| A_23_P208706 | BAX | BCL2 associated X, apoptosis regulator | -0.257 | 8.38E-04 | -0.467 | 5.43E-04 | -0.359 | 5.66E-03 |
| A_23_P258698 | MANBA | mannosidase beta | 9.52E-04 | 5.83E-04 | 1.03E-02 | |||
| A_19_P00323413 | PTPN14 | protein tyrosine phosphatase, non-receptor type 14 | -0.159 | 9.97E-04 | -0.156 | 3.87E-03 | -0.192 | 2.26E-03 |
| A_23_P153964 | INHBB | inhibin beta B subunit | 1.48E-03 | 1.25E-02 | 3.90E-03 | |||
| A_23_P376599 | RALBP1 | ralA binding protein 1 | 1.65E-03 | 9.60E-04 | 1.01E-03 | |||
| A_24_P142228 | RPL13 | ribosomal protein L13 | -0.161 | 2.07E-03 | -0.14 | 5.52E-03 | -0.137 | 4.01E-03 |
| A_23_P69521 | CCNI | cyclin I | -0.127 | 2.14E-03 | -0.132 | 9.97E-04 | -0.113 | 9.58E-03 |
| A_33_P3361746 | TRPS1 | transcriptional repressor GATA binding 1 | 2.18E-03 | 3.70E-03 | 1.19E-02 | |||
| A_23_P128956 | ZFYVE1 | zinc finger FYVE-type containing 1 | 3.24E-03 | 1.72E-02 | 2.38E-03 | |||
| A_23_P214666 | RPS18 | ribosomal protein S18 | -0.174 | 3.35E-03 | -0.144 | 1.74E-02 | -0.145 | 1.66E-02 |
| A_33_P3390570 | KMT2A | lysine methyltransferase 2A | -0.155 | 4.17E-03 | 2.03E-05 | -0.199 | 5.33E-04 | |
| A_33_P3344831 | TMEM45A | transmembrane protein 45A | 5.00E-03 | 8.13E-03 | 4.77E-04 | |||
| A_23_P35148 | TAF13 | TATA-box binding protein associated factor 13 | 5.16E-03 | 6.81E-03 | 9.50E-04 | |||
| A_23_P217015 | SET | SET nuclear proto-oncogene | -0.175 | 5.19E-03 | -0.439 | 7.38E-09 | -0.35 | 2.28E-03 |
| A_23_P77103 | SORD | sorbitol dehydrogenase | -0.184 | 5.22E-03 | -0.174 | 7.63E-04 | -0.18 | 2.69E-03 |
| A_21_P0001545 | LOC149351 | 6.60E-03 | 2.69E-03 | 2.13E-03 | ||||
| A_23_P207387 | GHDC | GH3 domain containing | 7.08E-03 | 1.13E-02 | 7.23E-04 | |||
| A_19_P00317052 | RNF213 | ring finger protein 213 | -0.183 | 7.40E-03 | -0.164 | 1.59E-02 | -0.164 | 1.89E-02 |
| A_23_P46871 | SLC29A3 | solute carrier family 29 member 3 | 7.57E-03 | 1.17E-02 | 1.40E-02 | |||
| A_21_P0000240 | SNORD100 | small nucleolar RNA, C/D box 100 | 8.18E-03 | 1.61E-02 | 1.14E-02 | |||
| A_23_P138435 | ZMIZ1 | zinc finger MIZ-type containing 1 | -0.126 | 1.04E-02 | -0.153 | 1.65E-03 | -0.125 | 1.66E-02 |
| A_33_P3234667 | ZKSCAN1 | zinc finger with KRAB and SCAN domains 1 | -0.152 | 1.07E-02 | -0.184 | 1.08E-03 | -0.185 | 7.75E-03 |
| A_24_P276816 | RCOR3 | REST corepressor 3 | 1.07E-02 | 1.42E-03 | 2.27E-03 | |||
| A_33_P3225760 | PCDH18 | protocadherin 18 | 1.08E-02 | 4.89E-04 | 5.24E-04 | |||
| A_33_P3210278 | SYNE2 | spectrin repeat containing nuclear envelope protein 2 | -0.196 | 1.17E-02 | -0.175 | 1.16E-02 | -0.166 | 1.14E-02 |
| A_23_P123563 | RPS6 | ribosomal protein S6 | -0.101 | 1.18E-02 | -0.131 | 2.09E-03 | -0.143 | 1.80E-03 |
| A_23_P501822 | JUP | junction plakoglobin | -0.154 | 1.31E-02 | -0.233 | 4.65E-03 | -0.26 | 1.36E-03 |
| A_24_P128563 | KPNA6 | karyopherin subunit alpha 6 | 1.64E-02 | 1.14E-02 | 3.65E-03 | |||
| A_23_P161190 | VIM | vimentin | -0.131 | 1.68E-02 | -0.179 | 7.25E-03 | -0.151 | 6.93E-03 |
Fold changes (FC) are actually log2 transformed fold changes, therefore if a FC is positive (in bold) the probe is over-expressed in the tested condition compared to the control, whereas it is under-expressed when a FC is negative. Probes differentially expressed for both concentrations (10 nM and 10 μM) are displayed with a grey background.
Upstream regulators provided by Ingenuity Pathway Analysis in the 10 genes differentially expressed at both concentrations (10 nM and 10 μM) for the three bisphenols (A, F and S).
| Upstream Regulator | Molecule Type | P-value of overlap | Target molecules in dataset |
|---|---|---|---|
| beta-estradiol | chemical—endogenous mammalian | 4.82E-03 | CCNI,INHBB,SET,SORD |
| APP | other | 4.98E-03 | HSPG2,KMT2A,SET |
| ESR1 | ligand-dependent nuclear receptor | 1.51E-02 | CCNI,INHBB,SORD |
| Vegf | group | 1.02E-03 | ACAN,INHBB,KMT2A |
| TGFB1 | growth factor | 2.87E-02 | ACAN,HSPG2,INHBB |
| PAX3 | transcription regulator | 3.10E-03 | HSPG2,PTPN14 |
| AGT | growth factor | 1.45E-02 | HSPG2,INHBB |
| GDF9 | growth factor | 1.11E-04 | HSPG2,INHBB |
| dihydrotestosterone | chemical—endogenous mammalian | 2.09E-02 | CCNI,INHBB |
| LY294002 | chemical—kinase inhibitor | 1.83E-02 | ACAN,INHBB |
| IL1B | cytokine | 4.99E-02 | ACAN,HSPG2 |